FDA Approvals - 14 Drugs Identified As Most Urgently Needing Study For Off-label
14 Drugs Identified As Most Urgently Needing Study For Off-label Use, Stanford Professor Says (Medical News Today)
Physicians and policy-makers know that drugs are frequently prescribed to treat certain diseases despite a lack of FDA approval - a practice known as off-label prescribing. Yet they say the problem is so big they don't know how to begin tackling it. But a potential game plan now exists.
FDA Accepts Filing And Grants Priority Review For DX-88 For Hereditary Angioedema (Medical News Today)
Dyax Corp. (NASDAQ: DYAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review.